In yesterday’s Wall Street session, Fresenius Medical Care AG & Co. KGaA ADR (NYSE:FMS) shares traded at $19.74, up 0.46% from the previous session.
21 analysts cover Fresenius Medical Care AG & Co. KGaA ADR (NYSE:FMS), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $38.57 and a low of $12.74, we find $21.32. Given the previous closing price of $19.65, this indicates a potential upside of 8.5 percent. FMS stock price is now 2.51% away from the 50-day moving average and -9.85% away from the 200-day moving average. The market capitalization of the company currently stands at $11.58B.
The stock has received a hold rating from 9 analysts and a buy rating from 7. Brokers who have rated the stock have averaged $22.54 as their price target over the next twelve months.
A total of 0.07% of the company’s stock is owned by insiders.
On Wednesday morning Fresenius Medical Care AG & Co. KGaA ADR (NYSE: FMS) stock kicked off with the opening price of $19.59. During the past 12 months, Fresenius Medical Care AG & Co. KGaA ADR has had a low of $14.82 and a high of $27.72. As of last week, the company has a debt-to-equity ratio of 0.93, a current ratio of 1.37, and a quick ratio of 1.02. According to the stock market information, the enterprise value for the company is $24.05B, which is based on a 18.72 price-to-earnings ratio, a 18.35 price-to-earnings-growth ratio, and a beta of 1.08. The fifty day moving average price for FMS is $19.26 and a two-hundred day moving average price translates $21.90 for the stock.
The latest earnings results from Fresenius Medical Care AG & Co. KGaA ADR (NYSE: FMS) was released for Sep, 2023. According to the Medical Care Facilities Company, earnings per share came in at $0.31, missing analysts’ expectations of $0.34 by -0.03. This compares to $0.49 EPS in the same period last year. The net profit margin was 3.01% and return on equity was 4.20% for FMS. The company reported revenue of $5.37 billion for the quarter, compared to $5.13 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4.67 percent. For the current quarter, analysts expect FMS to generate $5.54B in revenue.
Fresenius Medical Care AG & Co. KGaA ADR(FMS) Company Profile
Fresenius Medical Care AG & Co. KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
